EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Safety of 12‐Months Administration of Ashwagandha ( Withania somnifera ) Standardized Root Extract in Healthy Adults: A Prospective, Observational Study

Jaising Salve, Sanjeev Kale, Banwari Lal Prajapati, Adele Sparavigna, Mark Savant, John Ademola, Deepak Langade

Phytotherapy Research · 2026-08 · 40 (8) · 4802-4812

DOI: 10.1002/ptr.70096 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Phytotherapy Research, online erschienen am 08.10.2025. Verfasst von Jaising Salve und 6 weiteren Autor:innen. Beteiligte Einrichtung: Prakruti Care Hospital, Thane, India. Hauptthemen laut MEDLINE: Plant Extracts, Withania. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ashwagandha, an adaptogen, is an important herb of Ayurveda used as a Rasayana for its various health benefits. This prospective, multi‐center, observational clinical study evaluates the safety (clinical and laboratory) of a standardized Ashwagandha Root Extract (ARE) on long‐term administration over 12 months. Male and female adults ( N = 191) aged between 18 and 65 years were included in the study. Clinical assessments were done at baseline, followed by monthly for 12 months, whereas laboratory and other study assessments were done at baseline, 6 and 12 months. The primary outcome was the clinical adverse events reported by the patients, whereas secondary outcomes were Clinical Global Impression—Improvement scale (CGI‐I), health‐related Short Form‐12 Quality of Life (SF‐12 QoL), and laboratory estimations of serum for cortisol, hepatic, renal, and thyroid function. ARE administration for 12 months reported 18 mild adverse events, which were resolved without intervention. The study reported no clinical significant changes in serum alanine transaminases (baseline: 31.31 ± 9.28 IU /L, end of study: 33.68 ± 6.80 IU /L), aspartate transaminases (baseline: 30.61 ± 7.18 IU/L, end of study: 29.02 ± 4.63 IU/L). Serum cortisol levels decreased significantly ( p < 0.001), while lipid profile and plasma glucose levels remained unaffected. Serum testosterone (free and total) significantly increased ( p < 0.05). SF ‐12 scores demonstrated significant improvements at 12 months ( p < 0.001), indicating enhanced health‐related quality of life. CGI assessment indicated overall improvement in 68.7% of patients, particularly notable in those aged ≥ 50 years. This study validates the long‐term safety of ARE use over 12 months. Trial Registration: ClinicalTrials.gov identifier: CTRI/2022/10/046180; NCT06244147.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plant ExtractsWithaniaHumansFemaleAdultMiddle AgedMaleProspective StudiesPlant RootsQuality of LifeAdolescentYoung AdultAgedAlanine TransaminaseHydrocortisoneAspartate Aminotransferases

Stichwörter der Autor:innen

AshwagandhaCGI‐ISF‐12long‐term safety

Substanzen

Plant ExtractsAshwagandhaAlanine TransaminaseHydrocortisoneAspartate Aminotransferases

Autor:innen und Institutionen

  • Prakruti Care Hospital, Thane, India.
  • D. Y. Patil University School of Medicine, Navi Mumbai, India.
  • CLINI-TON Multispeciality Clinic, Jaipur, Rajasthan, India.
  • DERMING SRL Institute of Clinical Research and Bioengineering, Milan, Italy.
  • San Francisco Research Institute, San Francisco, California, USA.

Zitieren

APA

Salve, J., Kale, S., Prajapati, B. L., Sparavigna, A., Savant, M., Ademola, J., & Langade, D. (2026). Safety of 12‐Months Administration of Ashwagandha ( Withania somnifera ) Standardized Root Extract in Healthy Adults: A Prospective, Observational Study. Phytotherapy Research, 40(8), 4802-4812. https://doi.org/10.1002/ptr.70096

Vancouver

Salve J, Kale S, Prajapati BL, Sparavigna A, Savant M, Ademola J, et al. Safety of 12‐Months Administration of Ashwagandha ( Withania somnifera ) Standardized Root Extract in Healthy Adults: A Prospective, Observational Study. Phytotherapy Research. 2026;40(8):4802-4812. doi:10.1002/ptr.70096

BibTeX
@article{Salve2026,
  author = {Salve, Jaising and Kale, Sanjeev and Prajapati, Banwari Lal and Sparavigna, Adele and Savant, Mark and Ademola, John and Langade, Deepak},
  title = {Safety of 12‐Months Administration of Ashwagandha ( Withania somnifera ) Standardized Root Extract in Healthy Adults: A Prospective, Observational Study},
  journal = {Phytotherapy Research},
  year = {2026},
  volume = {40},
  number = {8},
  pages = {4802--4812},
  doi = {10.1002/ptr.70096}
}
Kostenlos starten →